Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of the UK’s access to monoclonal antibody therapies as an alternative to covid-19 vaccines.

The Therapeutics Taskforce continues to monitor a range of COVID-19 therapeutics, including monoclonal antibodies, aimed at different stages of the treatment pathway. There has been a collaboration with the Vaccines Taskforce to assess the potential of neutralising monoclonal antibodies to provide passive immunity as an alternative to COVID-19 vaccines. We continue to work closely with the cross-agency group RAPID C-19, to assess evidence from clinical trials and delivery to patients, following regulatory approval.

We are in contact with a number of manufacturers to ensure that United Kingdom patients have access to COVID-19 therapeutics as evidence continues to emerge.